Dyne Therapeutics, Inc.(DYN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DYN Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Dyne Therapeutics, Inc. (DYN), a Healthcare sector company. DYN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Dyne Therapeutics, Inc. reports net income of $-178.6M, free cash flow of $-131.8M. Top institutional holders of DYN by reported 13-F value include T. Rowe Price Investment Management, BlackRock, Jupiter Topco, based on the most recent SEC filings. DYN trades on the Nasdaq exchange and files with the SEC under CIK 1818794. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DYN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dyne Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-178.6M
Free Cash Flow
Q2 2026
$-131.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-40.6% YoYOperating Income
-36.1% YoYEPS (Diluted)
-3.0% YoYTotal Assets
+71.7% YoYTotal Debt
Op. Cash Flow
-37.9% YoYFree Cash Flow
-37.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-446.2M -40.6% | $-317.4M -34.5% | $-235.9M -40.4% | $-168.1M -12.6% | $-149.3M -151.2% | $-59.4M |
| Operating Income | $-468.2M -36.1% | $-343.9M -42.0% | $-242.2M -41.6% | $-171.0M -14.0% | $-150.0M -155.8% | $-58.6M |
| EPS (Diluted) | $-3.47 -3.0% | $-3.37 +14.7% | $-3.95 -22.3% | $-3.23 -10.2% | $-2.93 | — |
| Total Assets | $1.19B +71.7% | $691.2M +318.7% | $165.1M -46.1% | $306.3M -28.0% | $425.7M +20.5% | $353.3M |
| Total Debt | $148.9M | $0.00 | — | — | — | — |
| Operating Cash Flow | $-403.2M -37.9% | $-292.4M -55.4% | $-188.2M -22.5% | $-153.6M -28.5% | $-119.6M -157.1% | $-46.5M |
| Free Cash Flow | $-405.1M -37.4% | $-294.7M -56.0% | $-188.9M -20.5% | $-156.7M -27.2% | $-123.2M -158.4% | $-47.7M |
Get alerted when DYN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Dyne Therapeutics, Inc. including:
Top Institutional Holders of DYN
T. Rowe Price Investment Management, Inc.
$686.6M30,912,287 shBlackRock, Inc.
$275.5M12,404,330 shJupiter Topco LLC
$266.6M11,997,738 shFMR LLC
$248.9M11,207,000 shSTATE STREET CORP
$165.6M7,458,263 shOrbis Allan Gray Ltd
$155.6M7,006,542 shAtlas Venture Life Science Advisors, LLC
$151.0M6,800,099 shVANGUARD CAPITAL MANAGEMENT LLC
$140.2M6,310,969 shTCG Crossover Management, LLC
$102.5M4,615,144 shVANGUARD PORTFOLIO MANAGEMENT LLC
$89.9M4,048,428 sh
| Fund | Value | Shares |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | $686.6M | 30,912,287 |
| BlackRock, Inc. | $275.5M | 12,404,330 |
| Jupiter Topco LLC | $266.6M | 11,997,738 |
| FMR LLC | $248.9M | 11,207,000 |
| STATE STREET CORP | $165.6M | 7,458,263 |
| Orbis Allan Gray Ltd | $155.6M | 7,006,542 |
| Atlas Venture Life Science Advisors, LLC | $151.0M | 6,800,099 |
| VANGUARD CAPITAL MANAGEMENT LLC | $140.2M | 6,310,969 |
| TCG Crossover Management, LLC | $102.5M | 4,615,144 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $89.9M | 4,048,428 |
More Healthcare Companies
View all Healthcare →Put DYN on your watchlist
Track score changes the day Dyne Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DYN a good stock to buy?
13F Pro's AI-powered analysis of Dyne Therapeutics, Inc. (DYN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DYN are available on the DYN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DYN is classified as a mid company.
Which hedge funds own DYN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DYN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Dyne Therapeutics, Inc.'s investment landscape.